Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years — United States, January–March 2021

Mark W. Tenforde, Samantha M. Olson, Wesley H. Self, H. Keipp Talbot, Christopher J. Lindsell, Jay S. Steingrub, Nathan I. Shapiro, Adit A. Ginde, David J. Douin, Matthew E. Prekker, Samuel M. Brown, Ithan D. Peltan, Michelle N. Gong, Amira Mohamed, Akram Khan, Matthew C. Exline, D. Clark Files, Kevin W. Gibbs, William B. Stubblefield, Jonathan D. CaseyTodd W. Rice, Carlos G. Grijalva, David N. Hager, Arber Shehu, Nida Qadir, Steven Y. Chang, Jennifer G. Wilson, Manjusha Gaglani, Manjusha Gaglani, Kempapura Murthy, Nicole Calhoun, Arnold S. Monto, Emily T. Martin, Anurag Malani, Richard K. Zimmerman, Fernanda P. Silveira, Donald B. Middleton, Yuwei Zhu, Dayna Wyatt, Meagan Stephenson, Adrienne Baughman, Kelsey N. Womack, Kimberly W. Hart, Miwako Kobayashi, Jennifer R. Verani, Manish M. Patel

Research output: Contribution to journalArticlepeer-review

23 Scopus citations

Abstract

Adults aged ≥65 years are at increased risk for severe outcomes from COVID-19 and were identified as a priority group to receive the first COVID-19 vaccines approved for use under an Emergency Use Authorization (EUA) in the United States (1-3). In an evaluation at 24 hospitals in 14 states,* the effectiveness of partial or full vaccination† with Pfizer-BioNTech or Moderna vaccines against COVID-19-associated hospitalization was assessed among adults aged ≥65 years. Among 417 hospitalized adults aged ≥65 years (including 187 case-patients and 230 controls), the median age was 73 years, 48% were female, 73% were non-Hispanic White, 17% were non-Hispanic Black, 6% were Hispanic, and 4% lived in a long-term care facility. Adjusted vaccine effectiveness (VE) against COVID-19-associated hospitalization among adults aged ≥65 years was estimated to be 94% (95% confidence interval [CI] = 49%-99%) for full vaccination and 64% (95% CI = 28%-82%) for partial vaccination. These findings are consistent with efficacy determined from clinical trials in the subgroup of adults aged ≥65 years (4,5). This multisite U.S. evaluation under real-world conditions suggests that vaccination provided protection against COVID-19-associated hospitalization among adults aged ≥65 years. Vaccination is a critical tool for reducing severe COVID-19 in groups at high risk.

Original languageEnglish (US)
Pages (from-to)674-679
Number of pages6
JournalMMWR Recommendations and Reports
Volume70
Issue number18
DOIs
StatePublished - 2021
Externally publishedYes

ASJC Scopus subject areas

  • Epidemiology
  • Health(social science)
  • Health, Toxicology and Mutagenesis
  • Health Information Management

Fingerprint

Dive into the research topics of 'Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years — United States, January–March 2021'. Together they form a unique fingerprint.

Cite this